atezolizumab,cyclophosphamide,blinatumomab,axicabtagene ciloleucel,venetoclax,lisocabtagene maraleucel,brexucabtagene autoleucel,nivolumab,obinutuzumab,zilovertamab,pembrolizumab,ibrutinib,vedolizumab
roche,amgen,takeda,merck,bms,oncternal therapeutics,astellas,janssen,gilead,abbvie,daiichi sankyo
['atezo', ' ibru', 'cll', 'leukemia', 'venetoclax', 'nivolumab', 'nivo', 'blinatumomab', 'zilovertamab', 'pembro', 'breyanzi', 'axicabtagene ciloleucel', 'lisocabtagene', 'cyclophosphamide', 'obinu', 'zuma-2', 'brexucabtagene autoleucel', 'dlbcl', ' vedo']
treatment for #richter syndrome
a lot of new trials going on! so many options. still a lot to learn in this pathology! #ash22 
Microbiólogo y Médico @UniAndes, Internista @FSFB_salud, Hematólogo de @HematoCAUSA en @HHospitalet, Colaboro @ProyectoIdun #HSCT #Infections #CARTcells #GvHD